Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab);Deplezione inaspettata e persistente di linfociti B CD20+ dopo somministrazione di una minima dose di anticorpi anti-CD20 (Rituximab)

Reumatismo

Volumn 61, Issue 4, 2009, Pages 306-308

  Bruzzese, V ^a   Pepe, J ^a  

^a NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

Author keywords

Allergic reaction; Depletion CD20; Minimum dose of rituximab

Indexed keywords

ANTIRHEUMATIC AGENT; CD20 ANTIGEN; MONOCLONAL ANTIBODY; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CASE REPORT; CHEMICALLY INDUCED DISORDER; FEMALE; HUMAN; LYMPHOCYTOPENIA; MIDDLE AGED;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTIRHEUMATIC AGENTS; B-LYMPHOCYTES; FEMALE; HUMANS; LYMPHOPENIA; MIDDLE AGED;

EID: 77956221722     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multi center, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54: 2793-806.
2. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 613-20.
3. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine relase syndrome in patients with B cell chronic lymphocyte leukaemia and high lymphocyte counts after treatment with an anti CD 20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94: 2217-24.
4. Keystone E, Roy F, Emery P, Furst ED, van Vollehoven R, Balthon J. et al. Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis. Arthritis Rheum 2007; 56: 3896-908.